Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 34-39

  Mahaffey, Christopher M ^a,b   Mahaffey, Nichole C ^b   Holland, William ^b   Zhang, Hongqiao ^a   Gandara, David R ^b   MacK, Philip C ^b   Forman, Henry Jay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Keap1; MRP3; Nrf2; NSCLC; p53

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; PROTEIN P53; RNA; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER SURGERY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE CONTROL; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 84555206038     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318233d753     Document Type: Article

References (20)

1. Gerk PM, Vore M. Regulation of expression of the multidrug resistanceassociated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002;302:407-415. (Pubitemid 34787202)
2. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-6919. (Pubitemid 29274984)
3. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2:685-698.
4. Young LC, Campling BG, Voskoglou-Nomikos T, et al. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999;5:673-680. (Pubitemid 29131979)
5. Sullivan GF, Amenta PS, Villanueva JD, et al. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998;4:1393-1403. (Pubitemid 28265221)
6. Sullivan GF, Yang JM, Vassil A, et al. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 2000;105:1261-1267. (Pubitemid 30266079)
7. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008;105:13568-13573.
8. Mahaffey CM, Zhang H, Rinna A, et al. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med 2009;46:1650-1657.
9. Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009;15:3423-3432.
10. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1- NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
11. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-1309. (Pubitemid 351346836)
12. Mahaffey CM, Davies AM, Lara PN Jr, et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007;8:548-553. (Pubitemid 350292228)
13. Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008;135:1358-1368; 1368.e1351-e1354.
14. Tirumalai R, Rajesh Kumar T, Mai KH, et al. Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Toxicol Lett 2002;132:27-36. (Pubitemid 34655429)
15. Zhang H, Court N, Forman HJ. Submicromolar concentrations of 4-hydroxynonenal induce glutamate cysteine ligase expression in HBE1 cells. Redox Rep 2007;12:101-106. (Pubitemid 46210366)
16. Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010;9:336-346.
17. Li J, Johnson D, Calkins M, et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 2005;83:313-328. (Pubitemid 40227901)
18. Kang KW, Lee SJ, Park JW, et al. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 2002;62: 1001-1010. (Pubitemid 35222491)
19. Kumar B, Koul S, Khandrika L, et al. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-1785. (Pubitemid 351416563)
20. Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002;511:45-62. (Pubitemid 34241512)